hemophilia Flashcards

(33 cards)

1
Q

normal physiology

A
  • Process of preventing blood loss should occur as soon as the wound is created
  • Should be a tightly regulated process (turn on/off)
  • Process should only happen at the site of the wound
  • Clot should dissolve when no longer needed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

describe hemophilia

A

rare inherited bleeding diathesis that results in unusual susceptivity to bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

define hemophilia A

A

deficiency in FVIII = reduced/absent FVIIIa = reduced catalytic efficiency of FIXa = limited activation of FX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

define hemophilia B

A

deficiency in FIX = reduced catalytic efficiency of FIXa = limited activation of FX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what causes hemophilia (what is not activated) ?

A
  • coagulation cascade cannot function properly =

- intrinsic pathway not activated, not enough fibrin produced, above normal bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is necessary to diagnose hemophilia?

A

less than 50% of normal protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

how do we classify the severity of hemophilia?

what are the classifications?

A
  • based on the levels of FVIII or FIX (as predicts risk of furture bleeding events)
  • mild, moderate, severe
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

protein levels used to define mild hemophilia are:

A

levels of 5-50% of normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

protein levels used to define moderate hemophilia are:

A

levels of 1-5% of normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

protein levels used to define severe hemophilia are:

A

levels less than 1% of normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

hemophilia A and B are what type of genetic disease? what does this mean?

A
  • monogenetic

- means mutation in one single gene is implicated in the disease process

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

where is the mutation responsible for hemophilia?
what type of mutation is most common?
other types?

A
  • mutation in the F8/F9 gene on the X chromosome
  • point mutations are most common
  • others = large or small deletions, insertions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

in what pattern are mutations for hemophilia inherited?

what does this lead to?

A
  • via X-linked recessive patterns

- leads to deficiency of the functional FVIII or FIX proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

explain male inheritance of hemophilia

A

one altered gene is enough to cause hemophilia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

explain female inheritance of hemophilia

A
  • rare as its unlikely for a female to have 2 mutated versions of the gene
  • females who are carriers are generally asymptomatic (only 20-30% show signs of bleeding)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

who’s more likely to have hemophilia men or women?

A

men bc only one X chromosome

17
Q

would it be practical to asses hemophilia patients mrna for mutations? why or why not?

A
  • no
  • mRNA transcripts are large, also,
  • only cells that produce the protein (liver cells) will express the mRNA
  • thus, FVIII and FIX mRNA won’t be present in the blood
  • would have to do a liver biopsy instead which is very invasive
18
Q

would it be practical to use a dna sample to detect molecular mutations in a hemophilia patient? why or why not?

A
  • yes
  • dna can be obtained from simple blood draw (extracted from peripheral blood mononuclear cells)
  • could then use PCR & next gen sequencing to determine the sequence of the F8 or F9 genes and compare them to a reference
19
Q

F8 gene codes for? smaller or bigger than F9 gene?

A
  • FVIII protein

- 26 exons (bigger)

20
Q

F9 gene codes for? smaller or bigger than F8 gene?

A
  • FIX protien

- 8 exons (smaller)

21
Q

what mutation presents for the majority of severe hemophilia cases? why?

A
  • F8 intron inversion
  • F8 found at the end of X chromosome so its more succeptible to inversion
  • F8 also large
  • most happen at intron 22 - largest intronic region in the gene
22
Q

what is the mechanism for detecting inversions? (4)

A

(1) isolate dna from wbcs in blood draw
(2) incubate dna w restriction enezyme (cuts dna into smaller peices)
(3) run fragments through electrophoresis gel
(4) reference dna to healthy dna

23
Q

what are the clinical applications of hemophilia? (major symptoms) (2)

A
  • spontaneous bleeding - localized to joints and soft tissue

- provoked bleeding - can be result of trauma or surgery

24
Q

what is the goal of treatment for hemophilia patients?

A

to maintain therapeutic levels of FVIII and FIX for sustained periods of time - to ensure coagulation cascade can function properly

25
two methods of treatment for hemophilia are:
(1) on demand therapy: treating pateints as they experience bleeding events (2) preventative therapy: infusion of clotting factors to prevent bleeding events - proteins derrived from donated human plasma or through recombinant protein production by mamilian cells
26
what is the level of clotting factor infusion to prevent spontaneous bleeding?
1-5%
27
what is the target level of clotting factor infusion to prevent provoked bleeding?
10%
28
limitations to protein replacement therapy are:
- must be administered IV - short 1/2 life - need frequent repeated IV therapy (FVIII = 12hrs, FIX = 24 hours) - body can recognize replacement as foreign - can be expensive - not everyone has access - transmission of infectious disease (HIV, hepatitis)
29
what are other treatment options?
- PEGylation (prolonged half life) - emicizumab (mimetic) - fitusarin (rebalance) - gene therapy (endogenous protein production)
30
explain PEGylation
- PEGylation = chemical modification of FVIII protein through addition of PEG polymerase chains - these block the interactions with FVIII clearence receptors increasing their 1/2 life - still a protein replaement therapy tho so has limitations
31
explain emicizumab | what are its benefits?
- emicizumab = bispecific antibody that binds FX and FIXa - its a partial FVIII mimetic molecule (mimics action) - increases catalytic activity of intrinsic terase complex and increases FXa formation - benefits = subcutaneous administration, longer 1/2 life, act in presence of antiFVIII antibodies, low immunogenicity
32
explain fitusarin
-siRNA molecule that acts to inhibit production of antithrombin to reinstate balance of coagulants and anticoagulants
33
explain gene replacement therapy
- we use viral gene therapy with AAV (rep & cap genes replaced with promoter and therapeutic transgene) - insert therapeutic dna into viral vector, capsid, then IV to patient - delivers virus and new dna to target cell - target cell will make the therapeutic protein